Ionis Pharmaceuticals, Inc. IONS
27.44 USD -0.89 (-3.14%)
Nov 12, 2026, 10:49 AM EST
27.37 Day range 28.56
27.37 52-week range 86.74
- YTD
- -65.31%
- 1 year
- -62.24%
News
zacks.com Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings IONS plunges as slower Tryngolza sales, reduced guidance and disappointing Wainua royalties rattle investors.
seekingalpha.com AMG TimesSquare Mid Cap Growth Fund Q3 2026 Portfolio Update During this quarter, AMG TimesSquare Mid Cap Growth Fund performed in line with the Russell Midcap® Growth Index. Our leading contributors were software and health care technology companies that…
defenseworld.net Ionis Pharmaceuticals (NASDAQ:IONS) Stock Falls 7.3% Following Analyst Downgrade Shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) traded down 7.3% during trading on Tuesday after The Goldman Sachs Group lowered their price target on the stock from $58.00 to…
benzinga.com Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41 Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $58 to $41.
benzinga.com Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75 Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $104 to $75.
benzinga.com TD Cowen Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $53 TD Cowen analyst Yaron Werber maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $84 to $53.- benzinga.com Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $70 Oppenheimer analyst Jay Olson maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $70.
globenewswire.com Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a…
benzinga.com RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $85 to $60.
prnewswire.com IONS SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ionis Pharmaceuticals Ionis topped third-quarter revenue estimates with roughly $243 million in sales, yet IONS shareholders took losses as the same report showed a $110 million net loss and a more than 50% cut to…- benzinga.com Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80 Wells Fargo analyst Yanan Zhu maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $95 to $80.
benzinga.com HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $70 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $100 to $70.
businesswire.com Ionis to present at upcoming investor conferences CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global…
fool.com Ionis: 3 Key Takeaways for Long-Term Investors Ionis lowered 2026 TRYNGOLZA revenue guidance to approximately $50 million. DAWNZERA's third-quarter product sales rose 40% to $37 million.
seekingalpha.com Ionis Pharmaceuticals: Q3 Triggers The Latest Selloff On Tryngolza Disappointment Ionis Pharmaceuticals, Inc. stock plunged over 25% after Q3 earnings, despite beating revenue and EPS expectations and reaffirming 2026 guidance. IONS slashed 2026 Tryngolza sales guidance by more…
prnewswire.com Ionis Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ionis Pharmaceuticals (IONS) Ionis told investors in July that TRYNGOLZA was "on track" for $100 million to $110 million in 2026 sales. On November 9, it lowered that target to roughly $50 million.
seekingalpha.com Ionis Pharmaceuticals, Inc. (IONS) Q3 2026 Earnings Call Transcript Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2026 Earnings Call November 9, 2026 9:00 AM EST Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO &…
benzinga.com Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals Inc. (NASDAQ:IONS) stock is trading at a 52-week low after the company lowered Tryngolza (olezarsen) 2026 product sales guidance.
benzinga.com Why Is Ionis Pharmaceuticals Stock at a 52-Week Low on Monday? Ionis Pharmaceuticals stock hits a 52-week low after halving 2026 Tryngolza guidance, despite beating Q3 earnings estimates and posting 55% revenue growth.
benzinga.com Nasdaq 100 Jumps 3% as Chips Rebound; Nvidia Lags Most Since DeepSeek: Stock Market Today Wall Street rebounds from last week's rout as SOXX jumps 7%, while Nvidia slides on a CEO probe for its worst day versus the S&P 500 since DeepSeek.
marketbeat.com What Ionis Pharmaceuticals (IONS) Said on Its Q3 Earnings Call Ionis Pharmaceuticals NASDAQ: IONS lowered its 2026 sales forecast for TRYNGOLZA after a slower-than-expected launch in severe hypertriglyceridemia, while pushing its target for sustained positive…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
zacks.com Ionis Pharmaceuticals (IONS) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its…
globenewswire.com Ionis Pharmaceuticals (IONS) Shares Drop Following Sharp Reduction in TRYNGOLZA Sales Forecast – Kehoe Law Firm, P.C. Investigating PHILADELPHIA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P. C. is investigating potential securities claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company")…
zacks.com Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.61 per share a year ago.
barrons.com Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
benzinga.com Ionis Pharmaceuticals Q3 Adj. EPS $(0.40) Beats $(1.21) Estimate, Sales $243.000M Beat $182.117M Estimate Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(1.21) by 66.94 percent. This is a 34.43 percent increase over losses…- benzinga.com Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $916.396M Est Ionis Pharmaceuticals (NASDAQ:IONS) affirms FY2026 sales outlook from $875.000 million-$900.000 million to $875.000 million-$900.000 million vs $916.396 million estimate.
businesswire.com Ionis reports third quarter 2026 financial results and highlights progress on key programs CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026.…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
zacks.com Curious about Ionis Pharmaceuticals (IONS) Q3 Performance? Explore Wall Street Estimates for Key Metrics Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of…
benzinga.com This CME Group Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday Analysts upgraded Ionis, CME Group, DigitalOcean, Prologis and Zions Bancorporation, issuing new or revised price targets.
benzinga.com BMO Capital Upgrades Ionis Pharmaceuticals to Outperform, Raises Price Target to $66 BMO Capital analyst David Lebowitz upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Market Perform to Outperform and raises the price target from $54 to $66.- benzinga.com Ionis Pharmaceuticals Receives EMA CHMP Positive Opinion Recommending Indication Extension For TRYNGOLZA For Treatment Of Adult Patients With Severe Hypertriglyceridemia Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
benzinga.com Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease Ionis and Roche report positive Phase 3 IMAgINATION trial interim results for sefaxersen in treating primary IgA nephropathy.
benzinga.com Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks – Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney…
benzinga.com Ionis to Seek Expedited FDA Review for ALS Drug Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.- benzinga.com JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70 JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
- benzinga.com Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80 Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.
- benzinga.com Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85 Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.
- benzinga.com Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104 Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.
benzinga.com Why Is Eli Lilly Stock Falling Tuesday? Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
benzinga.com Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56 Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.
benzinga.com Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
benzinga.com BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54 BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.
benzinga.com Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
benzinga.com Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.- benzinga.com Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85 Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.